KRAS AND BRAF MUTATIONAL ANALYSES IN A PHASE II TRIAL OF FIRST-LINE FOLFOXIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)

被引：0
|
作者：
Salvatore, L. [1 ]
Loupakis, F. [1 ]
Cremolini, C. [1 ]
Lupi, C.
Masi, G. [1 ]
Sensi, E. [2 ]
Stasi, I [3 ]
Fornaro, L. [1 ]
Vasile, E. [1 ]
Schirripa, M. [1 ]
Truscelli, K. [4 ]
Giannini, R. [2 ]
Baldi, G. G. [3 ]
Altavilla, A. [4 ]
Ciarlo, A. [5 ]
Granetto, C. [6 ]
Fea, E. [6 ]
Fontanini, G. [2 ]
Basolo, F. [2 ]
Falcone, A. [1 ]
机构：
[1] Univ Pisana, Ist Toscano Tumori, UO Oncol Med Univ 2, Azienda Osped, Pisa, Italy
[2] Univ Pisana, Azienda Osped, UO Anat Patol, Sperimentale Univ, Pisa, Italy
[3] Ist Toscano Tumori, UO Oncol Med, Azienda USL 6, Livorno, Italy
[4] Univ Roma La Sapienza, UO Oncol Med, Dipartimento Med Sperimentale & Patol, Rome, Italy
[5] Osped Misericordia & Dolce, UO Oncol Med, Prato, Italy
[6] Osped S Croce & Carle, UO Oncol Med, Cuneo, Italy
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] OXALIPLATIN AND CAPECITABINE (XELOX) PLUS BEVACIZUMAB (BEVA) FOR ELDERLY PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (mCRC): BOXE, A PHASE II TRIAL
    Rosati, Gerardo
    Cordio, Stefano
    Leo, Silvana
    Daniele, Bruno
    Butera, Alfredo
    [J]. ANNALS OF ONCOLOGY, 2011, 22 : v104 - v104
  • [42] Intensified First Line Therapy of the metastatic colorectal Cancer with FOLFOXIRI plus Bevacizumab
    Ruessel, J.
    [J]. ONKOLOGE, 2015, 21 (04): : 334 - 335
  • [43] Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer
    Kito, Yosuke
    Satake, Hironaga
    Taniguchi, Hiroya
    Yamada, Takeshi
    Horie, Yoshiki
    Esaki, Taito
    Denda, Tadamichi
    Yasui, Hisateru
    Izawa, Naoki
    Masuishi, Toshiki
    Moriwaki, Toshikazu
    Mori, Keita
    Yamazaki, Kentaro
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (02) : 277 - 284
  • [44] Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer
    Yosuke Kito
    Hironaga Satake
    Hiroya Taniguchi
    Takeshi Yamada
    Yoshiki Horie
    Taito Esaki
    Tadamichi Denda
    Hisateru Yasui
    Naoki Izawa
    Toshiki Masuishi
    Toshikazu Moriwaki
    Keita Mori
    Kentaro Yamazaki
    [J]. Cancer Chemotherapy and Pharmacology, 2020, 86 : 277 - 284
  • [45] Effect of KRAS and NRAS mutational status on first-line treatment with FOLFIRI plus cetuximab in patients with metastatic colorectal cancer (mCRC): New results from the CRYSTAL trial
    Ciardiello, Fortunato
    Lenz, Heinz-Josef
    Kohne, Claus-Henning
    Heinemann, Volker
    Tejpar, Sabine
    Esser, Regina
    Beier, Frank
    Stroh, Christopher
    Duecker, Klaus
    Van Cutsem, Eric
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [46] Bevacizumab (BV) maintenance (M) after first-line chemotherapy (CT) plus BV for metastatic colorectal cancer (mCRC) patients (pts): A meta-analysis of individual pts data (IPD) from three phase III studies.
    Salvatore, Lisa
    Bria, Emilio
    Sperduti, Isabella
    Hinke, Axel
    Hegewisch-Becker, Susanna
    Aparicio, Thomas
    Le Malicot, Karine
    Boige, Valerie
    Koeberle, Dieter
    Baertschi, Daniela
    Dietrich, Daniel
    Tortora, Giampaolo
    Arnold, Dirk
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [47] Treatments (tx) after progression to first-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts): A pooled analysis of TRIBE and TRIBE-2 studies by GONO
    Rossini, D.
    Lonardi, S.
    Antoniotti, C.
    Santini, D.
    Tomasello, G.
    Aprile, G.
    Moretto, R.
    Prete, A. A.
    Granetto, C.
    Urbano, F.
    Borelli, B.
    Zaniboni, A.
    Randon, G.
    Buonadonna, A.
    Ritorto, G.
    Barbara, C.
    Latiano, T. P.
    Bordonaro, R.
    Falcone, A.
    Cremolini, C.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 215 - 215
  • [48] Treatments (tx) after progression to first-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts): A pooled analysis of TRIBE and MOMA studies by GONO group.
    Rossini, Daniele
    Moretto, Roberto
    Cremolini, Chiara
    Zagonel, Vittorina
    Tonini, Giuseppe
    Ricci, Vincenzo
    Aprile, Giuseppe
    Lonardi, Sara
    Tomasello, Gianluca
    Dell'Aquila, Emanuela
    Allegrini, Giacomo
    Bergamo, Francesca
    Mancini, Marialaura
    Antoniotti, Carlotta
    Ronzoni, Monica
    Zaniboni, Alberto
    Marmorino, Federica
    Bustreo, Sara
    Mori, Elena
    Alfredo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [49] Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
    Masi, Gianluca
    Loupakis, Fotios
    Salvatore, Lisa
    Fornaro, Lorenzo
    Cremolini, Chiara
    Cupini, Samanta
    Ciarlo, Andrea
    Del Monte, Francesca
    Cortesi, Enrico
    Amoroso, Domenico
    Granetto, Cristina
    Fontanini, Gabriella
    Sensi, Elisa
    Lupi, Cristiana
    Andreuccetti, Michele
    Falcone, Alfredo
    [J]. LANCET ONCOLOGY, 2010, 11 (09): : 845 - 852
  • [50] Intermittent or continuous panitumumab (PAN) plus FOLFIRI for first-line treatment of patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC): A randomized phase II trial (IMPROVE)
    De Stefano, A.
    Nasti, G.
    Febbraro, A.
    Rosati, G.
    Giuliani, F.
    Santini, D.
    Aprile, G.
    Scartozzi, M.
    Silvestris, F.
    Luppi, G.
    Lolli, I.
    Mastroianni, C.
    Leo, S.
    Montesarchio, V.
    Gridelli, C.
    Pozzo, C.
    Sperti, E.
    Giannarelli, D.
    Budillon, A.
    Avallone, A.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
12345